Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer

This comprehensive retrospective analysis compiled data from 920 patients across 9 prospective clinical studies to evaluate the efficacy of sustained-release triptorelin formulations in testosterone suppression in patients with advanced prostate cancer. The formulations evaluated included 1-, 3-, and 6-month preparations.

The results demonstrated that sustained-release triptorelin formulations achieved testosterone suppression to castration levels (<50 ng/dL) in the vast majority of patients, with a substantial proportion reaching the more stringent threshold of <20 ng/dL. Suppression was consistently maintained throughout treatment, regardless of the formulation used.

• Castration rates (testosterone <50 ng/dL) exceeded 95% after the first month
• The 6-month formulation (triptorelin pamoate) demonstrated efficacy comparable to shorter-duration formulations
• Testosterone "escape" episodes were rare and generally transient
• The safety profile was consistent with the GnRH agonist class

The data from this pooled analysis reinforced triptorelin's position as a reliable therapeutic option for androgen suppression in advanced prostate cancer. The availability of formulations with different administration intervals offers flexibility in clinical management, and the ability to achieve ultra-low testosterone levels is particularly relevant, given that lower levels are associated with better oncological outcomes.